


HTA 2019 in Europe – Harmonisation Ahead?

Key Note Speech



Annika Nowak

European Commission, Brussels,
BELGIUM

Member of the Cabinet of
Commissioner Andriukaitis

Chair



Dr Alexander Natz, LL.M.

EUCOPE – European Confederation
of Pharmaceutical Entrepreneurs,
Brussels, BELGIUM

Secretary General

Speakers



Dr Hannah Brühl

Federal Joint Committee (G-BA),
Berlin, GERMANY

Scientific Advisor, Pharmaceuticals
Department



Sheela Upadhyaya

National Institute for Health and
Care Excellence (NICE), London,
GREAT BRITAIN

Associate Director Highly Specialised
Technology (HST) Program



Dr Anna Bucsecs

Project Advisor to MoCA
Mechanism of Coordinated Access
to Orphan Medicinal Products,
AUSTRIA



Heidi L. Wagner, J.D.

Global Executive and Government
Affairs Expert, USA

Member of the Board of Directors,
EUCOPE



Christian Hill

MAP BioPharma, Cambridge,
GREAT BRITAIN

Chief Executive Officer and
EU Market Access Expert

HTA 2019 in Europe – Harmonisation Ahead?

Aims and objectives

The Commission's proposal for a Regulation on Health Technology Assessment (HTA) strengthened the discussion on whether and how to harmonise HTA in Europe.

This conference informs you on the EU collaboration models to date, the Commission's proposal and what to expect as of 2019.

Participate in this conference to learn how far we have come with regard to harmonising HTA in the EU (and beyond).

Who should attend?

This conference addresses the needs of employees in the pharmaceutical industry responsible for market access activities in the various national European markets.

Those involved in value-assessment preparation and pricing activities will benefit particularly from this conference.

Your programme 09:00 - 17:00

European HTA and pricing collaborations to date: What has been achieved?

Dr Alexander Natz, LL.M.

- BeNeLuxA initiative; EUnetHTA initiatives and successes
- EURIPID Guidance Document on external reference pricing

Strengthening EU cooperation on HTA: The Commission's proposal

Annika Nowak

- Reasoning behind strengthening EU cooperation
- Which pharmaceuticals and medical devices are involved?
- How to reach an agreement on common clinical assessments
- Current status of the draft regulation on health technology assessments

European Early Dialogues experiences: A model of success?

Dr Hannah Brühl

National HTA in England: What of EU cooperation?

Sheela Upadhyaya

- Summary of the NICE HST program
- Will NICE continue to collaborate on the joint HTA?

Access for innovative medicines to the EU market

Christian Hill

- Paid-for and compassionate-use early access – pros and cons
- Managed access agreements during and after the HTA
- Lessons learned and applied to ATMPs

European orphan drug collaboration to date: What has been achieved with MoCA?

Dr Anna Bucsis

HTA, pricing and funding for orphan drugs in Europe – an industry perspective

Heidi L. Wagner, J.D.

Registration: +49 6221 500 555 or email: service@forum-institut.de

Yes, I will attend

☐ HTA 2019 in Europe - Harmonisation Ahead?

☐ Yes, I agree that FORUM Institut may inform me about events by:
☐ email; and/or ☐ telephone. I may withdraw my consent at any time

Name

Position/Department

Company

Street address

Postal Code/City/Country

Tel. No.

E-Mail

Contact person at the office

Date/Signature

■ **Registration: +49 6221 500-500**

■ **Conference-No. 18 09 236**

■ **Date/Venue:**

Friday, 14 September 2018
08:30 registration; 09:00-17:00 conference
Hotel Palace
Budapester Str. 45 · 10787 Berlin
Tel.: +49 30 2502-1190 · Fax: +49 30 2502-1199

■ **Fee:**

€ 1,290.00 (+German VAT) incl. course documentation (incl. free download) as well as mid-session refreshments, lunch and certificate.

■ **Questions and information:**

Dr. Henriette Wolf-Klein
Department Manager Pharmaceuticals & Healthcare
Tel. +49 6221 500 680 · h.wolf-klein@forum-institut.de

■ **Cancellation Policy:**

Our general terms and conditions apply (as of 01.01.2016) and are available upon request. We can send them to you anytime or you can find them on the internet at www.forum-institut.com/t&c